Tuesday, December 15, 2020

Investor Ideas #Potcasts #Podcast - Episode 507, #Cannabis News and #Stocks on the Move: (CSE: $PULL.C) (OTCQB: $DRVD) (CSE: $HOLL.C) (CSE: $STEM.C)

Investor Ideas #Potcasts #Podcast - Episode 507, #Cannabis News and #Stocks on the Move: (CSE: $PULL.C) (OTCQB: $DRVD) (CSE: $HOLL.C) (CSE: $STEM.C)

 


Delta, Kelowna, BC, December 15, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/121520-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/12151PULL-DRVD-HOLL-STEM.asp

 

Hear the investor ideas potcast on Spotify

 

Hear Investor ideas cannabis potcast on iTunes  

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

In today’s podcast we will be looking at a few private and public company announcements.

 

 

Pure Extracts Technologies Corp. (CSE: PULL), a plant-based extraction company focused on cannabis, hemp, and the rapidly emerging functional mushroom sector, announced their support of Health Canada’s proposed intent to revise the Special Access Programme (SAP) and related regulations to permit certain authorized uses of psilocybin-assisted psychotherapeutic treatments. The intended SAP revision, announced on December 11th, could lead to important new medical applications, particularly in the complex and growing mental health sector.

Health Canada’s announcement could act as a milestone achievement driving advanced research initiatives forward. This includes several ongoing clinical trials that consistently indicate breakthrough therapy potential of psilocybin-assisted psychotherapy for a number of mental health patients suffering from conditions where conventional therapies have failed or have proven unsuitable.

The proposed SAP update emphasizes the strategic importance of Pure Extracts engagement of a globally recognized operations, compliance, and regulatory consulting firm to advise on the Company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (CDSA). The CDSA and its Regulations provide the framework for legal access to controlled substances, and the control and regulation of production, distribution, and sale. One of Health Canada’s responsibilities is to provide the licensing and oversight framework for the legal production of controlled substances.

Upon acceptance, a Dealer’s License could allow Pure Extracts to engage in the following activities:

      Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction

      Research and manufacture of controlled substances such as psilocybin and psilocin

      Business to business sale of controlled substances, including by export

      Sale of controlled substance via pharmacies

Expanding upon the strategic importance of the SAP review, Pure Extracts recently announced a collaboration with Dr. Alexander MacGregor as a key scientific advisor to the Company. Pure Extracts and Dr. MacGregor are collaborating on the development and research of optimum psilocybin extraction methodologies in preparation to service the needs of the rapidly advancing growth and demand in the sector.

As previously noted, Dr. MacGregor is the Dean of Faculty, a distinguished Professor of Biopharmaceutics, and current President of the Toronto Institute of Pharmaceutical Technology (TIPT) – North America’s premier post-graduate institute of pharmaceutical sciences, technology and research. He is also the CEO of TIPT’s parent company, Transpharm Canada Inc., which holds a Health Canada Drug Establishment License, a Cannabis Drug License, and a Dealer’s License issued under the Controlled Drugs and Substances Act (CDSA). Transpharm Canada conducts clinical trials, drug development and is licensed to possess psychedelic drug compounds. 

Pure Extracts CEO Ben Nikolaevsky states, “The Special Access Programme may prove to be the tipping point and fundamental milestone event that eventually transforms an entire segment of the medical community’s outlook towards the treatment of mental health conditions. With greater and more open access to trials, researchers can move towards larger and more comprehensive studies eventually including thousands of patient candidates. Through multiple large-scale studies, we see great promise in determining treatment safety, efficacy, and desired outcomes. Our research suggests a broad spectrum of products encompassing multiple formulations will be required to service demand across potentially intensive therapies through to microdosing protocols. Exact formulations and high-quality products will be required, and that is fundamentally the sort of work we understand and excel at. Here at Pure Extracts, we believe in the future of the mushroom-based drug development sector and are committed to building value based on the growing number of positive indicators for future success.”

Driven Deliveries, Inc. (OTCQB: DRVD), one of California's fastest-growing e-commerce cannabis retailers and direct-to-consumer logistics companies, today announced it has secured preliminary approval for a new e-commerce delivery hub in the Fresno County region.  Driven has also submitted its application for this new cannabis non-storefront retail license to the State of California which is expected to be approved in the near-term.  Plans for Driven's acquisition by Stem Holdings, Inc. (OTCQX: STMH) (CSE: STEM) later this month are continuing on schedule, creating Driven By Stem trading under Stem's current symbols.

 

This new strategically-located hub will enable Driven to serve central California with greater efficiency and speed, and will be led by key experienced employees transferring to this location to ensure a smooth and flawless launch.  This is expected to create 50 new jobs in the local area and afford significant cost savings in both general and administrative costs, as well as local taxes, with savings of $1.2 million annually vs. servicing this market from a remote hub.

 

 "Securing a license in Central California is a key component in Driven's focus on building market share with increasing operational efficiencies in new and current markets," commented Salvador Villanueva, interim CEO of Driven, and founder of its Budee e-commerce brand acquired earlier this year.  "Our focus on expanding our footprint in California with our Budee and Ganjarunner e-commerce stores as well as new markets will be the key to driving profitability in 2021," he concluded.

 

"We are pleased that this first step in our plan to integrate Driven into Stem's operations is nearing completion," stated Adam Berk, CEO of Stem Holdings.  "Sal and the team have made great strides over the last 60 days as part of our 'On Your Mark' initiative to prepare for a seamless assimilation of Driven that will quickly build value for our shareholders," he remarked.

 

Driven currently has delivery hubs located in Oakland and Los Angeles, California, and will be expanding to the Oregon market in which Stem already operates by year-end.

 

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) has its roots in the birthplace of the American biker, and Easyriders has been the definitive voice of motorcycle culture for half a century. As part of Easyriders' 50th-anniversary celebration, the Company signed an exclusive agreement with Hollister Biosciences to introduce a national line of cannabis products that embody the biker spirit and ethos.  It is anticipated that the new line will make its debut next month with pre-rolls and mini pre-rolls, followed by a cannabis tattoo balm that's applied directly to the skin after new ink, with a full line of products coming in 2021.

The Company feels the market potential for these products is significant, but so is the cultural significance considering the two companies involved.

 

Easyriders magazine debuted shortly after the groundbreaking 1969 film Easy Rider in which Peter Fonda and Dennis Hopper portray bikers traveling across the American Southwest. Similarly, Hollister Biosciences is based in Hollister, California, home to an infamous 1947 biker rally that birthed the outlaw biker image and inspired the Marlon Brandon film The Wild One. Cannabis, which had developed its own outlaw culture a few decades before, became a staple among bikers in the late '60s onward. As epitomized in the pages of Easyriders, this vibrant biker culture grew beyond its outlaw origins to inspire an independent spirit that embraces exploration, Americana and the sense of freedom that only comes from riding.

 

This is a culture that accepts nothing less than total authenticity. That includes its choice in cannabis, and that is why Hollister Biosciences and Easyriders were destined to take this ride together. From their historic roots in biker culture to their embrace of its visual iconography, these companies will offer the first truly authentic cannabis products for one of the most iconic cultures in modern American history.

 

"My vision for Hollister has always been to pay homage to the amazing biker culture that has permeated the global landscape over the past few decades by combining it with amazing cannabis products," says Carl Saling, the Co-Founder, CEO and Director of Hollister Biosciences. "Easyriders is one of the most iconic and recognizable global biker brands. We are proud to be their exclusive cannabis partner, and we look forward to producing a truly authentic experience across the cannabis SKUs we develop and distribute across America."

 

Hollister Biosciences, whose products are currently found in nearly 300 dispensaries in California and more than 80 in Arizona, takes a seed-to-shelf approach that carefully scales up small-farm style production that meets the highest quality standards. As part of the new agreement, the company will introduce Easyriders pre-rolls and tattoo balms into the California market in early 2021 with a full line of products to follow. Like an eastbound ride on Route 66, Arizona comes next, and the rest of the American markets will follow.

 

Pepper Foster, President of Easyriders, stated, "My vision for Easyriders has been to pay homage to the 50 years of this iconic magazine and to Joe Teresi who launched Easyriders in the late 1960s. The first magazine hit the stands in June 1970, and 50 years later, we are proud to carry the torch, expanding upon that yen to be devoid of restraint by taking a broader look at what it means to be a biker in the 21st century while staying connected to our original roots. In continuing our commitment to authenticity, we are proud and excited to partner with another iconic brand, Hollister. We invite you to take the ride with us. Ride hard. Ride fast."

 

The terms of the deal are; 2-year exclusive agreement on all cannabis products in the US with an 80:20 net revenue split in favour of Hollister with options to renew for subsequent terms.

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 


  



Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

 

Thursday, December 10, 2020

Investorideas.com - South Carolina Lawmakers Pre-file Medical Cannabis Bills Ahead of 2021 Legislative Session

Investorideas.com - South Carolina Lawmakers Pre-file Medical Cannabis Bills Ahead of 2021 Legislative Session

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; #Podcast 506 (OTC: $LRSV) (TSX: $AH.TO) (TSXV: $KHRN.V) (TSX: $AVCN.TO) (CSE: $PULL.C)

 



 

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; #Podcast 506 (OTC: $LRSV) (TSX: $AH.TO) (TSXV: $KHRN.V) (TSX: $AVCN.TO) (CSE: $PULL.C)

 

Delta, Kelowna, BC, December 10, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/121020-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/12101LRSV-AH-KHRN-AVCN-PULL.asp

 

Hear the investor ideas potcast on Spotify

 

Hear Investor ideas cannabis potcast on iTunes  

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

In today’s podcast we will be looking at a few private and public company announcements.

 

 

Link Reservations Inc. (OTC: LRSV), a provider of cannabidiol (CBD) products specifically tailored for pets, announced that it is current with all of its OTC Market filings and has achieved "Current Information" status, with no risk or yields signs associated with the stock on OTCMarkets.com.

 

"I am delighted that the Company is current once again and we can focus back on the business," commented Rene Lauritsen, LinkResPet CEO. "We continue to explore the potential for growth in the CBD and wellness market and are currently assessing a number of avenues through which we can expand our presence, including further developing our product range," he added.

 

The Company has updated all financial reports and disclosure statements and will resume operations with its LinkResPet brand, making further announcements as new developments arise.

 

The Company also recently raised its Authorized Shares in order to issue shares to its CEO, Rene Lauritsen, for an acquisition that is pending which he initiated. These newly issued shares are restricted for one year per Rule 144 and if the acquisition is not completed the shares will be returned to treasury. As shareholders may note, LRSV's share structure had previously been unchanged for almost four years.

 

Aleafia Health Inc. (TSX: AH) (OTC: ALEAFannounced that it will commence cannabis exports to the Israeli medical cannabis market. The Company signed a binding letter of intent with Equinox International Ltd., a licensed British medical cannabis company with operations in the Israeli market.

 

Under the LOI, Equinox has committed to purchasing approximately 1,400 kg of dried flower in 2021. The first shipment to Equinox is expected to occur in Q1 2021 pending receipt of necessary import and export permits and completion of Aleafia’s cultivation cycle. Permit applications have already been submitted and will mark the first export of EU GACP-compliant dried flower grown at Aleafia’s Niagara Greenhouse facility.

 

Israel, the world’s fastest growing medical cannabis market, reached over 60,000 registered patients in 2020, from half that figure in 2018. It is also the largest net importer of cannabis globally, recently surpassing Germany.

 

Equinox International, in partnership with Aleafia Health, will establish an Israeli Land-to-Brand ecosystem covering supply, distribution, market leading brands and retail.

 

“Gaining market access to Israel, an incredibly dynamic country with a fast growing, highly innovative cannabis market, is something we’ve long aspired to,” said Aleafia Health CEO Geoffrey Benic. “Doing so with Equinox, an accomplished, internationally scaled partner, marks an exciting chapter as we commercialize Aleafia Health globally.”

 

“Equinox is delighted to form a Land-to-Brand strategic partnership with Aleafia Health,” said Equinox International CEO Xan Morgan. “Equinox is firmly positioned as a British champion and in partnership with Aleafia will be a leader in the Israeli cannabis market.”

 

The parties must now negotiate a definitive agreement concerning the supply of dried flower to Israel over a three-year term. They have agreed to negotiate the definitive agreement exclusively with one another for a period of 45 days.

 

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced that it has now successfully completed the import of its High THC medical cannabis product into Peru, with first prescriptions to be filled in December.

 

With today's announcement, Khiron becomes the first company to export High THC medical cannabis from Colombia and the only Colombian company to fill High THC prescriptions in Peru for commercial purposes. This expands the Company's product offering in Peru where sales of its High CBD product began in September 2020.

"This first shipment of Khiron's trusted High THC product into Peru represents a first in exporting High THC medical cannabis from Colombia and delivers on our strategy to increase our market impact in Peru, providing patients with reliable access to medical cannabis products. With an established pharmacy partner and data from medical cannabis prescriptions we have filled to date in Colombia, we know this will make a difference in improving the quality of life for patients in Peru," commented Alvaro Torres, Khiron CEO and Director.

 

As part of Khiron's Latin America expansion strategy, its High THC medical cannabis products were successfully imported into Peru as result of the Company completing all export, import and distribution requirements, including approved receipt of quotas for the Company's high THC medical cannabis by DIGEMID, Peru's drug regulatory authority. Khiron Peru is a GSP certified, registered pharmaceutical establishment, and Farmacia Universal has all required permits and licenses, including Good Manufacturing Practices (GMP) certification, to prepare magistral preparations with medical cannabis and distribute final products to patients through pharmacies under the previously announced agreement with Khiron.

 

The Company continues to expand medical cannabis doctor education, with almost 200 physicians from Peru having obtained their diploma accrediting completion of Khiron's medical education through the Company's program with Tecnologico de Monterrey. The Company's high THC products will focus on helping patients with serious conditions that include chronic pain, spasticity, PTSD, nausea, insomnia, anorexia and depression.

 

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announced the launch of its medical cannabis program in Colombia, under compound pharmacy legislation “Formulaciones Magistrales”, in which Avicanna will provide its standardized, industry-leading cannabinoid formulary to patients and the medical community. Additionally, this program includes the education and training of the medical community and a comprehensive patient support program.

 

Aras Azadian, CEO of Avicanna Inc., commented: “After 2 years of preparation, we are proud to be launching this complete program in a market that is very significant to us and to be doing so with a medical community that we have been working closely with for close to 3 years. We believe that this medical program will set the gold standard for advanced cannabinoid-based medicine in Colombia and will act as a proof of concept for planned expansions into other Latin American markets.”

 

The pharmaceutical cannabinoid preparations, which require physician prescription, will be commercialized through a range of business models including direct sales to patients, delivery to national pharmacies and delivery to third party medical institutions across Colombia. This comprehensive medical cannabis program is the first of its kind in Colombia to be educating and training third party health care practitioners on the efficacy of advanced cannabinoid-based medicine across various clinical indications and comorbidities and providing appropriate cannabinoid solutions. The target therapeutic areas include neurological disorders such as epilepsy, Parkinson’s disease, multiple sclerosis, psychiatric indications such as PTSD, anxiety, depression as well as chronic pain.

 

This first complete portfolio of advanced cannabinoid preparations comprises the same scientifically developed formulations as Avicanna’s Canadian RHO Phyto branded dosage forms including topicals, oil drops, sublingual sprays, and capsules in range of CBD only and CBD-THC ratios. The products are subjected to typical pharmaceutical drug development, including stability studies and preclinical analysis where they have demonstrated superior stability and bioavailability in comparison to basic MCT oil formulations. Avicanna continues to advance these formulations through real world evidence trials and further preclinical studies with leading Canadian institutions and clinicians. In addition to its R&D efforts, the Company continues to optimize its current formulas and expand its pipeline of products to include alternative delivery mechanisms. The active pharmaceutical ingredients for this program are sourced from Avicanna’s majority owned subsidiary Santa Marta Golden Hemp S.A.S., where the cannabinoids are extracted from organic and sustainably cultivated plants.

 

The final preparation of these products is completed through Avicanna’s own Good Production Practices (GPP) certified pharmacy lab in Bogota through its wholly owned subsidiary Avicanna LATAM S.A.S. (“Avicanna LATAM”), which is believed to be the first of its kind to be certified for cannabinoid preparations. The education and patient support programs are also managed and operated by Avicanna’s medical team to ensure the services meet Avicanna’s quality standards and complete the full vertical integration.

 

“At Avicanna, our focus has always been on patients, and today, with the launch of our medical program, patients in Colombia will have access to therapeutic alternatives that may contribute to the control of their comorbidities, improving their quality of life and solving possible unmet medical needs altogether. With that, we have established ourselves as a significant contributor to the health system in Colombia, where we intend to also introduce novel pharmaceutical forms and provide optimal care,” stated Dr. Carlos Maldonado, Senior Vice President, Clinical Development at Avicanna LATAM.

 

Pure Extracts Technologies Corp. (CSE: PULLannounced that it has engaged a globally recognized operations, compliance, and regulatory consulting firm to advise on the Company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (CDSA).

The CDSA and its Regulations provide, among other things, the framework for legal access to controlled substances, and the control and regulation of production, distribution, and sale. One of Health Canada’s responsibilities is to provide the licensing and oversight framework for the legal production of controlled substances.

Under this framework, a company is required to obtain a licence issued by Health Canada in order to conduct various activities with controlled substances. Licence holders are responsible for compliance with the CDSA and its Regulations as well as compliance with other applicable federal, provincial, and territorial legislation and municipal by-laws. The issued licence dictates activities, conditions, and restrictions for the licence holder depending on licence permissions.

A Dealer’s Licence could allow for the following activities:

      Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction

      Research and manufacture of controlled substances such as psilocybin and psilocin

      Business to business sale of controlled substances, including by export

      Sale of controlled substance via pharmacies

Pure Extracts CEO, Ben Nikolaevsky, remarked, “Having the support of one of Canada’s premiere consulting companies with subject matter proficiency in cannabis and other regulated consumer product industries assures that we will submit a fully-compliant Dealers Licence application to Health Canada in the shortest time possible. As a plant-based extractor bringing functional mushroom products to market in Q1 2021, we are very excited to be laying the groundwork for our move into the controlled substances world of psychedelics.”

Having the ability to do extraction research and development into psychedelic compounds such as psilocybin and psilocin will prepare Pure Extracts to work with partners such as medical doctors, pharmaceutical company and pharmacies as clinical trials lead to the legalization of psychedelics and the advancement of micro-dosing in the near future.

Submission of the Company’s Dealer’s Licence application is subject to compliance with applicable securities laws, including any necessary approvals by the CSE.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

 

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 


  


Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

#CBD #Stocks in the News: Link Reservations Inc/LinkResPet (OTC: $LRSV) Announces #OTC #Markets Current Information Reporting; @res_pet

#CBD #Stocks in the News: Link Reservations Inc/LinkResPet (OTC: $LRSV) Announces #OTC #Markets Current Information Reporting; @res_pet 

 

London, UK – December 10, 2020, Breaking  CBD stock news from Investorideas.com Newswire- Link Reservations Inc. (OTC: LRSV), a provider of cannabidiol (CBD) products specifically tailored for pets, is very pleased to announce that it is current with all of its OTC Market filings and has achieved "Current Information" status, with no risk or yields signs associated with the stock on OTCMarkets.com.

 

Read this news, featuring LRSV in full at https://www.investorideas.com/news/2020/cannabis/12101LRSV-OTC-Markets.asp

 

“I am delighted that the Company is current once again and we can focus back on the business", commented Rene Lauritsen, LinkResPet CEO. “We continue to explore the potential for growth in the CBD and wellness market and are currently assessing a number of avenues through which we can expand our presence, including further developing our product range", he added.

 

The Company has updated all financial reports and disclosure statements and will resume operations with its LinkResPet brand, making further announcements as new developments arise.

 

The Company also recently raised its Authorized Shares in order to issue shares to its CEO, Rene Lauritsen, for an acquisition that is pending which he initiated. If the acquisition is not completed the shares will be returned to treasury. As shareholders may note, LRSV’s share structure had previously been unchanged for almost four years.

 

To learn more about LinkResPet or to purchase CBD pet products, please visit: www.linkrespet.com or follow us on twitter at @res_pet.

About Link Reservations Inc.

Link Reservations Inc is CBD Petcare provider dedicated to improving the health and life conditions of pets worldwide. Developing and marketing hemp-based CBD products for cats, dogs and horses, the Company is currently present in Europe and in the US. A pioneer in the area, Link Reservations Inc products can be found under its brand LinkResPets (www.linkrespet.com). 

 

 

Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

 

Linkreservations Inc

400 Thames Valley Park Drive

Reading Berkshire RG6 1 PT

United Kingdom

Phone: +44 330 808 0897

 

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring LRSV is a paid for news release on Investorideas.com  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com and http://www.renewableenergystocks.com/

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others. 

 

 

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories